Article - 10/01/2011 Review: What does the cell factory of the future look like? A symposium on “Cell Factories of the Future” was held at the Laupheim-based company Rentschler Biotechnologie on 14th and 15th October 2010. The event attracted around 70 scientists from academia and industry and will now take place every two years. The symposium focused on new biomanufacturing developments and technologies, and included lectures on (animal) cells, cell factories and the future of recombinant protein production. https://www.gesundheitsindustrie-bw.de/en/article/news/review-what-does-the-cell-factory-of-the-future-look-like
Article - 03/12/2010 Review: Science meets Business Day 2010 (part II) How can plant physiologists and seed developers work together to achieve an understanding of the processes happening in the germinating plant embryo in order to improve the seed quality of sugar beet? How can virologists find new ways to switch off the flu virus and develop a marketable vaccine in cooperation with industrial partners?https://www.gesundheitsindustrie-bw.de/en/article/news/review-science-meets-business-day-2010-part-ii
Dossier - 29/11/2010 Drug safety and the difficulty of making ends meet Everybody wants safe drugs – manufacturers, doctors and patients. However, many dangers, both avoidable and unavoidable, make medicinal treatment a high-risk process, despite all best efforts and assertions. Not enough information on drug-related risks is available, and the estimated number of adverse drug reactions that go unreported is quite high.https://www.gesundheitsindustrie-bw.de/en/article/dossier/drug-safety-and-the-difficulty-of-making-ends-meet
Article - 29/11/2010 Against chronic liver inflammation and liver cancer Chronic hepatitis B and C are the major causes of liver cancer. In contrast to hepatitis B viruses, there is no hepatitis C virus vaccination available. New research carried out by Professor Bartenschlager and his colleagues from Heidelberg might give rise to new strategies for the development of vaccines and medications for the prevention and treatment of chronic hepatitis C virus infections.https://www.gesundheitsindustrie-bw.de/en/article/news/against-chronic-liver-inflammation-and-liver-cancer
Press release - 21/09/2010 immatics raises 54 million euros to advance its late stage clinical therapeutic cancer vaccine portfolio immatics biotechnologies GmbH a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer announced today that it has raised 53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics existing pipeline of advanced therapeutic cancer vaccine candidates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-raises-54-million-euros-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine-portf
Press release - 09/09/2010 China Medical City, Taizhou Taizhou is a commercial and industrial city of around 5 million inhabitants located in the Yantze River Delta about half way between Nanjing and Suzhou. Within the Taizhou city boundaries on a total area of 25 square kilometers China Medical City CMC a national-level pharmaceutical high-tech park is currently under construction. https://www.gesundheitsindustrie-bw.de/en/article/press-release/china-medical-city-taizhou
Press release - 08/09/2010 Prevention and Treatment of Chronic Hepatitis C GENOVAC and Inserm co-develop a novel antibody-based approach for prevention and treatment of chronic hepatitis C.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-and-treatment-of-chronic-hepatitis-c
Article - 30/08/2010 Diagnostics for the early detection of cervical cancer The Pap test is regarded as the most successful test for cancer ever, and has saved the lives of many women. However, the test is associated with several weaknesses. The Heidelberg-based in vitro diagnostics company mtm laboratories AG develops and commercialises highly sensitive and highly specific immunochemical tests that provide greater reliability. These tests have the potential to revolutionise the early detection of cervical cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/diagnostics-for-the-early-detection-of-cervical-cancer
Article - 23/08/2010 Antibiotics for the prevention of malaria Researchers from Heidelberg and Berlin have shown that if malaria-infected mice are administered an antibiotic, no parasites appear in the blood and the mice are protected from this life-threatening disease. The scientists believe that antibiotics also have the potential to strengthen the human immune system as well as making it possible to provide a natural needle-free vaccination against malaria.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotics-for-the-prevention-of-malaria
Press release - 02/08/2010 GMP Centre established in Tübingen The Good Manufacturing Practice Zentrum GMP-Zentrum GMP Centre of Tübingen University Hospital was officially opened on 16th July. The GMP-Zentrum was established to enable the production of individualised vaccines and antibodies according to the rules of good pharmaceutical practice for the treatment of cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gmp-centre-established-in-tuebingen
Press release - 21/07/2010 One Million for Cancer Research from Manfred Lautenschläger Foundation When Harald zur Hausen was awarded the Nobel Prize for Medicine in 2008, Manfred Lautenschläger spontaneously offered to support the Nobel laureate’s scientific work by funding a new research team. These funds will now go to Angelika Riemer, a young scientist who plans to advance the development of a vaccine which is able to cure existing infections with carcinogenic human papillomaviruses at the German Cancer Research Center (Deutsches…https://www.gesundheitsindustrie-bw.de/en/article/press-release/one-million-for-cancer-research-from-manfred-lautenschlaeger-foundation
Press release - 22/06/2010 CureVac starts Phase IIa with mRNA immunotherapeutic in Non-Small Cell Lung Cancer CureVac GmbH, the mRNA company, today announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the start of a Phase IIa trial for CV9201 to treat Non-Small Cell Lung Cancer (NSCLC).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-starts-phase-iia-with-mrna-immunotherapeutic-in-non-small-cell-lung-cancer
Dossier - 14/06/2010 Engineers of life Synthetic biology focuses on the development of biological systems with new defined characteristics assembled according to the principles of engineering. Synthetic biology has the potential to be used for a broad range of applications and has solutions in store for major problems of the future. It also fuels fears that human beings are playing the role of creators and going beyond natural boundaries. https://www.gesundheitsindustrie-bw.de/en/article/dossier/engineers-of-life
Press release - 02/06/2010 immatics enters Collaboration with the National Cancer Institute (NCI) immatics biotechnologies GmbH announced on June 2nd, 2010 that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-enters-collaboration-with-the-national-cancer-institute-nci
Article - 24/05/2010 Alternative CAM: chicken eggs to precede mouse experiments Researchers who test whether in vitro results can be transferred to living organisms prefer to use mice rats or rabbits. Many questions can be answered using the chorioallantoic membrane CAM of fertilised chicken eggs an alternative model to animal experiments that provides rapid results and only costs 50 cents per egg.https://www.gesundheitsindustrie-bw.de/en/article/news/alternative-cam-chicken-eggs-to-precede-mouse-experiments
Press release - 21/05/2010 The road to individualized tumour vaccines What are the typical cancer cell characteristics that our immune system is directed against? Using a new biochemical method, scientists from the Neurosurgery Department of the Heidelberg University Hospital and the German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ) are now able to answer this question for each individual patient. The method is expected to help identify new target structures for individualized tumour vaccines. https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-road-to-individualized-tumour-vaccines
Press release - 12/05/2010 CureVac raises EUR 27.6 Million in Financing Round CureVac GmbH, the mRNA vaccine company, today announced the closing of a EUR 27.6 million (US$ 35.25 million) financing round with its major shareholder, dievini Hopp BioTech holding GmbH & Co. KG.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-eur-27-6-million-in-financing-round
Article - 29/04/2010 The biopharmaceutical industry remained stable in times of crisis The German biopharmaceutical industry has come through 2009 without experiencing too many major slumps. The roaring growth of the biopharmaceutical industry in previous years has been replaced by more moderate growth. This is the result published by the 4th Medical Biotechnology report in 2010 compiled on behalf of the biotech interest group of the vfa bio Association of Research-Oriented Pharmaceutical Companies by the Boston Consulting Group. https://www.gesundheitsindustrie-bw.de/en/article/news/the-biopharmaceutical-industry-remained-stable-in-times-of-crisis
Article - 19/04/2010 Natural antibodies to treat Alzheimer’s Alzheimers disease is characterised by changes in the substance and structure of the brain that are caused by the depositing of protein plaques in the brain. Prof. Michael Przybylski and his team of researchers at the University of Constance have deciphered the structure of the site where mouse antibodies attach to the plaques subsequently causing them to dissolve. These findings will now be used to identify the binding structure of a component…https://www.gesundheitsindustrie-bw.de/en/article/news/natural-antibodies-to-treat-alzheimer-s
Article - 26/03/2010 How do killer cells manage to survive? It is not easy for the body to protect itself once a virus has broken through the body’s lines of defence and caused a chronic infection. This task is made even more difficult when the intruders are viral hepatitis pathogens that attack the liver, the place where immunological tolerance is induced. Jörg Reimann (physician) and Reinhold Schirmbeck (biologist) are working on the development of T-cell-mediated therapeutic vaccination strategies to…https://www.gesundheitsindustrie-bw.de/en/article/news/how-do-killer-cells-manage-to-survive
Article - 18/03/2010 Cancer treatment adapted to individual patient requirements There is still no treatment available for a number of non-Hodgkin B-cell lymphomas. Chemotherapy, which is the standard method of treating the lymphomas, has unpleasant side effects. Researchers led by Prof. Dr. Hendrik Veelken at the Freiburg University Medical Centre in cooperation with Freiburg-based CellGenix Technologie Transfer GmbH have developed a promising new treatment strategy. Results of the Phase I and the Phase II study, which has…https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-treatment-adapted-to-individual-patient-requirements
Article - 15/03/2010 Innovative navigation system enables gene shuttles to reach their destination If everything goes to plan the Department of Gene Therapy at the University of Ulm will soon lose a work group to industry. Florian Kreppels team plans to turn a particular technology into hard cash using a method that can do something other gene shuttles are unable to do namely transport their freight to a specific destination.https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-navigation-system-enables-gene-shuttles-to-reach-their-destination
Article - 15/03/2010 Campaign to eradicate malaria After many decades, efforts to develop an effective vaccine against malaria have finally brought researchers closer to their goal. However, the goal of eradicating malaria completely can only be reached through a complex strategy, to which researchers from Heidelberg are making intensive contributions.https://www.gesundheitsindustrie-bw.de/en/article/news/campaign-to-eradicate-malaria
Article - 15/03/2010 The first active immunisations against cancer The first anti-cancer vaccines were developed to prevent women from becoming infected with papillomaviruses and to protect them against cervical cancer. The development of vaccines can be traced back to the work of Nobel Laureate Harald zur Hausen and his colleagues at the German Cancer Research Centre in Heidelberg. But more development is required in the field of anti-cancer vaccines and this is why researchers worldwide are working on vaccines…https://www.gesundheitsindustrie-bw.de/en/article/news/the-first-active-immunisations-against-cancer
Dossier - 15/03/2010 Vaccine development As the recent discussion on the pros and cons of swine flu vaccinations has shown vaccinations are not very popular in Germany. However people tend to forget that no other medical development has helped people to the same extent as immunisation with vaccines has done. Examples include the discovery of the cow pox vaccination by Edward Jenner in 1796 and all the programmes that have been set up by the Global Alliance for Vaccines and Immunisation…https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccine-development
Article - 13/03/2010 Assembling life from building blocks? As part of its “Bioethics Forum”, the German Ethics Council recently held a meeting in Berlin to inform the public about the fundamentals of synthetic biology and potential ethical problems and consequences in terms of our ideas about life and mankind in general arising from the progress made in this new field of research. https://www.gesundheitsindustrie-bw.de/en/article/news/assembling-life-from-building-blocks
Dossier - 22/02/2010 Respiratory disease - congestion in the respiratory system Lung diseases are by far the most frequent cause of death worldwide. Every year three million people die from chronic obstructive pulmonary diseases 2.3 million die from lung cancer and 1.5 die from tuberculosis WHO World Health Organisation. There is no improvement in sight and experts believe that the number of deaths will continue to rise particularly in the case of chronic obstructive pulmonary diseases COPD lung cancer and tuberculosis TB.…https://www.gesundheitsindustrie-bw.de/en/article/dossier/respiratory-disease-congestion-in-the-respiratory-system
Press release - 04/02/2010 World Cancer Day: encouraging the prevention, detection and treatment of cancer World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/world-cancer-day-encouraging-the-prevention-detection-and-treatment-of-cancer
Article - 15/12/2009 Arming the immune system against cancer The theory that immune cells are able to attack tumours has long been a theory with only a minority of supporters. However, this theory is currently experiencing a renaissance. In the future, it might even be possible to specifically alter T-lymphocytes in order to improve their ability to identify and destroy certain tumour types. Prof. Dr. Hanspeter Pircher and his team at the Freiburg University Medical Centre are focusing on the development…https://www.gesundheitsindustrie-bw.de/en/article/news/arming-the-immune-system-against-cancer
Press release - 08/12/2009 Vaccination of honeybees against the Varroa mite is possible For the first time ever, honeybees were orally ‚vaccinated’ with a genetically engineered product that was later detected in the bloodsucking Varroa mite. This product is a DNA-plasmid that is normally used for man, horses, swine and also for fish. The inventor of this innovative DNA-vaccination system for bees is Matthias Giese, PhD, who launches his own Institute for Molecular Vaccines (IMV) in Heidelberg/Germany starting in 2010.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-of-honeybees-against-the-varroa-mite-is-possible
Article - 03/12/2009 Matthias Giese: DNA vaccine to combat worldwide honeybee deaths Varroa mites attach to the body of bees and weaken them by sucking hemolymph infecting them with viruses that are believed to be the cause of the mass death of European honeybee colonies. Matthias Giese of the Heidelberg-based Institute for Molecular Vaccines developed a DNA vaccine that might just lead to a breakthrough in the quest to get rid of the Varroa parasites. Giese tells us about his project in the following interview.https://www.gesundheitsindustrie-bw.de/en/article/news/matthias-giese-dna-vaccine-to-combat-worldwide-honeybee-deaths
Article - 14/11/2009 "A little naivety always helps" The biotech company CureVac based in Tuebingen is working on the development of a new tumour therapy based on RNA molecules. Dr. Ingmar Hoerr one of the scientists who founded CureVac tells Christoph Bächtle about the obstacles the young company had to overcome and the tough decisions that led to success. At the very start he tells us the company owes its origins to a huge dollop of luck.https://www.gesundheitsindustrie-bw.de/en/article/news/a-little-naivety-always-helps
Press release - 04/11/2009 CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer CureVac GmbH, the mRNA vaccine company, today announced that the German authorities approved the start of the Phase IIa trial in Prostate Cancer after assessment of the first safety data of lead candidate CV9103, a RNActive®-derived mRNA vaccine. Results so far from the Phase I show CV9103 to be safe and well tolerated.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-launches-phase-iia-mrna-vaccine-trial-in-prostate-cancer
Press release - 12/10/2009 Cancer Cells Suppress the Body’s Own Defense Mechanisms Cancer cells use tricks to evade the immune system. Thus, for example, they attract specific blood cells which suppress the body’s own defense mechanisms. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), collaborating with colleagues of the University Surgical Hospital in Heidelberg and an international research team, have investigated these processes in bowel cancer. The results of their research have now…https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-cells-suppress-the-body-s-own-defense-mechanisms
Press release - 12/10/2009 Immatics appoints Carsten Reinhardt as Chief Medical Officer The biopharmaceutical company immatics biotechnologies GmbH announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009. “I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-carsten-reinhardt-as-chief-medical-officer
Press release - 24/09/2009 Call for innovative technologies that address global health concerns The World Health Organization is seeking innovative technologies, in particular medical devices that offer solutions to global health concerns in low- and middle-income countries. The deadline for submission of proposals is January the 31st 2010.https://www.gesundheitsindustrie-bw.de/en/article/press-release/call-for-innovative-technologies-that-address-global-health-concerns
Article - 21/08/2009 Patenting and clinical trials go hand in hand Back when he was doing his degree thesis at the German Cancer Research Centre in Heidelberg the immunologist Prof. Peter Öhlschläger who now works at the University of Constance laid down the basic principles for developing an artificial gene for the treatment of cervical cancer. Prof. Öhlschläger is currently in the process of filing a patent for DNA vaccines for HPV. In the following interview the scientist says that the greatest challenges are…https://www.gesundheitsindustrie-bw.de/en/article/news/patenting-and-clinical-trials-go-hand-in-hand
Press release - 10/08/2009 How do immune cells recognise infectious pathogens? Scientists of the University of Heidelberg and the German Cancer Research Centre have clarified the functional principles of an important receptor for bacterial infections: immune cells recognise bacterial and viral pathogens with a receptor known as toll-like receptor 9 (TLR9), which mediates biochemical reaction chains in order to fend off intruders. This discovery made by the Heidelberg researchers paves the way to develop new anti-infective…https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-do-immune-cells-recognise-infectious-pathogens
Press release - 30/07/2009 Boehringer Ingelheim set to outpace the market again After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
Press release - 30/07/2009 Why do hepatitis virus infections become chronic? The German Research Foundation (DFG) has approved funding for a new research project at the Universities of Freiburg and Heidelberg. The researchers are working on improving our understanding of the mechanisms that lead to chronic virus infections: how do hepatitis viruses manage to evade immunological defence reactions and survive in the organism without damaging the organism?https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-do-hepatitis-virus-infections-become-chronic
Article - 30/07/2009 Keeping as many valuable attachments as possible The goal of many projects focusing on the purification of recombinant proteins is to rapidly and effectively remove substances and side products that would compromise the quality and quantity of biopharmaceutical compounds. A consortium of industrial and scientific partners is currently focusing on a different step in the biopharmaceutical production process: the goal is to keep as many as possible of the drugs’ ‘attachments’. The project focuses…https://www.gesundheitsindustrie-bw.de/en/article/news/keeping-as-many-valuable-attachments-as-possible
Article - 14/07/2009 Tiny particles are a weapon against tumours Prostate carcinoma is one of the most common malignant diseases claiming more than 84000 lives per year in the EU and the United States. In cooperation with the University of Constance the Thurgau Biotechnology Institute BITg is working on ways to remove prostate carcinomas and other tumours that are difficult to treat by using tiny particles made of biologically degradable polyester. Prof. Dr. Marcus Groettrup and his team of researchers have…https://www.gesundheitsindustrie-bw.de/en/article/news/tiny-particles-are-a-weapon-against-tumours
Article - 02/07/2009 A virus that hides while it waits for an opportunity to replicate Thomas Mertens, Medical Director of the Institute of Virology in Ulm, has a strong scientific and clinical interest in the human cytomegalovirus (HCMV), a big virus with a big impact which, despite its size, is overshadowed by known viruses such as the HI virus that is the object of research for Mertens’ colleagues. HCMV research is a challenging area where quick successes are rare.https://www.gesundheitsindustrie-bw.de/en/article/news/a-virus-that-hides-while-it-waits-for-an-opportunity-to-replicate
Article - 10/06/2009 Dirk Linke - a vaccine is ready - just in case There is a well-known saying: travel broadens the mind. This is not the only consequence of travel – the biochemist Dr. Dirk Linke from Tübingen travelled to India on holiday and brought back an idea for a new scientific project. Since his return, his idea, the possibility of developing a vaccine with a wide-ranging effect against some of the most frequent diarrhoea pathogens, has even generated financial backing from prominent supporters.https://www.gesundheitsindustrie-bw.de/en/article/news/dirk-linke-a-vaccine-is-ready-just-in-case
Press release - 28/05/2009 CureVac Begins Clinical Study with mRNA Vaccine CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-begins-clinical-study-with-mrna-vaccine
Article - 16/05/2009 Mykotown Greentech AG uses mycorrhiza to keep plants going Mykotown Greentech AG offer mycorrhizal preparations that protect the plants against dehydration and bacteria. The fungi also enhance plant growth. The plants provide the natural soil fungi with carbon while the fungi help the plant to capture nutrients and liquids from the soil.https://www.gesundheitsindustrie-bw.de/en/article/news/mykotown-greentech-ag-uses-mycorrhiza-to-keep-plants-going
Press release - 30/04/2009 In the tubular system of human cells Scientists from the Hygiene Institute at the Heidelberg University Hospital have succeeded for the first time ever in showing the three-dimensional architecture of the dengue virus replication and assembly sites in human cells. Their paper was recently published in the renowned journal “Cell Host & Microbes”. https://www.gesundheitsindustrie-bw.de/en/article/press-release/in-the-tubular-system-of-human-cells
Article - 02/02/2009 CureVac enters premier biotech league with new cancer vaccine At present active immunotherapy seems to produce the best results in the treatment of cancer. The Tübingen-based biotech company CureVac is now hoping to achieve a breakthrough in cancer therapy with a worldwide unique vaccine. The first clinical trials have recently commenced.https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-enters-premier-biotech-league-with-new-cancer-vaccine
Press release - 14/01/2009 IND Approval for CureVac CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/ind-approval-for-curevac
Press release - 10/12/2008 CureVac to Start First mRNA Vaccine Clinical Trial in Prostate Cancer The German regulatory authority has approved the Clinical Trial Application CTA to begin a Phase I clinical study with RNActive - derived mRNA vaccine CV9103. It will be tested in patients with hormone-refractory metastatic prostate cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-to-start-first-mrna-vaccine-clinical-trial-in-prostate-cancer